Cited 4 times in
Multimodality treatment with radiotherapy for huge hepatocellular carcinoma.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김미선 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 차지혜 | - |
dc.contributor.author | 최진섭 | - |
dc.date.accessioned | 2015-12-28T10:53:05Z | - |
dc.date.available | 2015-12-28T10:53:05Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/138233 | - |
dc.description.abstract | BACKGROUND: For huge hepatocellular carcinoma (HCC), therapeutic decisions have varied from local therapy to systemic therapy, with radiotherapy (RT) playing only a palliative role. In this study, we investigated whether multimodality treatment involving RT could be effective in huge HCC. RESULTS: This study was performed in 116 patients with HCC >10 cm. The number of patients in stage II, III and IV was 12, 54 and 50, respectively. RT was given as a combined modality in most patients. The median dose was 45 Gy, with 1.8 Gy per fraction. The median overall survival (OS) and progression-free survival (PFS) were 14.8 and 6.5 months, respectively. The median infield PFS was not reached. Infield failure, outfield intrahepatic and extrahepatic failure were observed in 8.6, 18.1, and 12.1% of patients, respectively. For OS and PFS, number of tumors, initial alpha-fetoprotein (AFP) level, treatment response, percent AFP decrement, and hepatic resection were significant prognostic factors. Tumor characteristics and treatment response were significantly different between long-term survivors and the other patients. CONCLUSION: Although huge HCC presents an aggressive clinical course, multimodality approaches involving RT can offer an opportunity for prolonged survival. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 82~89 | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Biomarkers, Tumor/blood | - |
dc.subject.MESH | Carcinoma, Hepatocellular/diagnosis | - |
dc.subject.MESH | Carcinoma, Hepatocellular/mortality | - |
dc.subject.MESH | Carcinoma, Hepatocellular/pathology* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/radiotherapy | - |
dc.subject.MESH | Carcinoma, Hepatocellular/therapy* | - |
dc.subject.MESH | Dose Fractionation | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hepatectomy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Liver Neoplasms/diagnosis | - |
dc.subject.MESH | Liver Neoplasms/mortality | - |
dc.subject.MESH | Liver Neoplasms/pathology* | - |
dc.subject.MESH | Liver Neoplasms/radiotherapy | - |
dc.subject.MESH | Liver Neoplasms/therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Medical Records | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Radiotherapy, Adjuvant* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Treatment Failure | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | alpha-Fetoproteins/metabolism | - |
dc.title | Multimodality treatment with radiotherapy for huge hepatocellular carcinoma. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학) | - |
dc.contributor.googleauthor | H J Han | - |
dc.contributor.googleauthor | M S Kim | - |
dc.contributor.googleauthor | J Cha | - |
dc.contributor.googleauthor | J S Choi | - |
dc.contributor.googleauthor | K H Han | - |
dc.contributor.googleauthor | J Seong | - |
dc.identifier.doi | 10.1159/000368150 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00444 | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A04009 | - |
dc.contributor.localId | A04199 | - |
dc.relation.journalcode | J02416 | - |
dc.identifier.eissn | 1423-0232 | - |
dc.identifier.pmid | 25427738 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/368150 | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Radiotherapy | - |
dc.subject.keyword | Multimodality treatment | - |
dc.contributor.alternativeName | Kim, Mi Sun | - |
dc.contributor.alternativeName | Seong, Jin Sil | - |
dc.contributor.alternativeName | Cha, Ji Hye | - |
dc.contributor.alternativeName | Choi, Jin Sub | - |
dc.contributor.affiliatedAuthor | Kim, Mi Sun | - |
dc.contributor.affiliatedAuthor | Seong, Jin Sil | - |
dc.contributor.affiliatedAuthor | Cha, Ji Hye | - |
dc.contributor.affiliatedAuthor | Choi, Jin Sub | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 87 | - |
dc.citation.number | Suppl 1 | - |
dc.citation.startPage | 82 | - |
dc.citation.endPage | 89 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, Vol.87(Suppl 1) : 82-89, 2014 | - |
dc.identifier.rimsid | 52327 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.